Genetic factors are understood to influence the patient's fatigue, with specific mutations identified in genes related to neurological function, methylation pathways, and liver detoxification.

**Specific Genetic Influences on Fatigue:**

*   **SCN9A Mutation:** A full genome analysis in March 2023 identified a sodium channel mutation in the SCN9A gene. This variant is considered highly likely to alter protein function, being very rare in humans, highly conserved, and predicted as such by computer algorithms. Variants in SCN9A can cause small fiber neuropathy, leading to exaggerated sensations, pain, and fatigue. This mutation is also linked to mitochondrial oxidation and dysfunction, which reduces aerobic capacity and helps explain many of the patient's complex and previously difficult-to-diagnose symptoms. SCN9A-targeted medications like gabapentin, duloxetine, sertraline, and amitriptyline have been considered for management.
*   **TNXB Variant:** A heterozygous variant in the TNXB gene (c.6074A>T, p.Asp2025Val) is considered a potential risk factor for fatigue in the patient. This variant is likely to alter protein function, being rare and conserved, and is thought to contribute to fatigue via vascular hypotension.
*   **Methylation and Liver Detoxification Pathway Gene Mutations:** A specialist in alternative care suggested that the patient's chronic fatigue issues are at least partly related to genetic polymorphism blocks in his methylation and liver detox cycles. A DNA test specifically targeting genes in the methylation cycle also revealed mutated genes. These mutations affect enzymes that metabolize various substances in the liver.
    *   **MAO A (Monoamine Oxidase A)**: The patient has a homozygous mutation (MAO A +/+). This enzyme is involved in breaking down serotonin, and imbalances can be associated with depression, aggression, anxiety, and OCD behavior. Depression and anxiety are symptoms the patient experiences that contribute to fatigue.
    *   **MTHFR (Methylenetetrahydrofolate reductase)**: The patient has a heterozygous mutation (MTHFR C677T +/-). This gene product is critical in the methylation cycle, helping to regulate homocysteine levels and potentially influencing levels of neurotransmitters like serotonin and dopamine. Reduced MTHFR enzyme activity can lead to reduced methylfolate production, which is a precursor for serotonin, norepinephrine, and dopamine synthesis. Supplementation with folic acid-based interventions or L-methylfolate may be required.
    *   **MTR/MTRR (Methionine Synthase/Methionine Synthase Reductase)**: The patient has multiple heterozygous mutations in MTRR (MTRR A66G +/-, MTRR H595Y +/-, MTRR K350A +/-). These genes work together in the methylation pathway to regenerate and utilize B12, and mutations can increase the need for B12. The patient's physician noted abnormalities in MTRR enzymes (important in homocysteine handling).
    *   **BHMT (Betaine Homocysteine Methyltransferase)**: The patient has multiple heterozygous mutations in BHMT (BHMT 2 +/-, BHMT 4 +/-, BHMT 8 +/-). This gene product is involved in a "short cut" through the methylation cycle and its activity can be affected by stress and cortisol levels. The patient's physician also noted abnormalities in BHMT enzymes.
    *   **COMT (Catechol-O-methyltransferase)**: The patient's Genecept Assay showed a Val/Val genotype, indicating high COMT activity. This enzyme is responsible for breaking down dopamine in the frontal lobes, and high activity can affect frontal lobe dopamine and working memory.
    *   **CBS (Cystathionine-beta-synthase)**: The patient has a homozygous mutation (CBS A360A +/+). Increased CBS activity can deplete other methylation pathway support like B12 and release toxic byproducts such as excess ammonia and sulfites.
    *   **SHMT (Serine Hydroxymethyltransferase)**: The patient has a homozygous mutation (SHMT C1420T +/+). Mutations affecting its regulation can interfere with the methylation cycle's balance, potentially leading to homocysteine accumulation and other imbalances.
    *   Supplementation with substances like Acetyl-Glutathione improved the patient's strength, extending his "4 hour day" to "7 hours". The patient is currently taking glutathione suppositories and SafeCell Glutathione, and methylB12 drops have also been recommended. The patient's current physician notes a strong belief from the patient that these supplements and medications are helping with strength and energy.

**Other Genetic Findings:**

*   **TNFRSF13B Variant:** A pathogenic variant (c.204dupA, p.Leu69ThrfsTer12) was found, resulting in protein loss of function. While typically associated with common variable immunodeficiency, it shows poor clinical correlation to the patient's specific phenotype but might be a contributing factor to his overall disease, which includes fatigue.

In summary, the genetic analyses point to specific gene mutations (SCN9A, TNXB, MAO A, MTHFR, MTR/MTRR, BHMT, COMT, CBS, SHMT) affecting neurological function, mitochondrial efficiency, vascular regulation, and critical methylation and detoxification pathways, which are believed to contribute significantly to the patient's chronic and persistent fatigue.